Streetbeat News

Products Services

REGN

Regeneron reports positive early clinical trial results for the combination of LAG-3 inhibitor Fianlimab and PD-1 inhibitor Libtayo, showing clinically meaningful and durable results across multiple clinical settings. The data will be presented at the 2023 ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:15 pm

REGN

Regeneron reports updated data from two Phase 2 expansion dose cohorts evaluating investigational linvoseltamab (formerly REGN5458) in patients with heavily pre-treated, relapsed/refractory multiple myeloma. The treatment demonstrated impressive efficacy at the recommended 200 mg dose in the LINKER-MM1 trial.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:14 pm

VSTM

Verastem has released updated data from Part A of its RAMP 201 trial, which focuses on the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:13 pm

TERN

Terns Pharmaceuticals announced the publication of a trial-in-progress abstract for TERN-701, an allosteric BCR-ABL, for the 2023 ASCO Meeting. The China Phase 1 trial has completed enrollment of Cohort 5 in the Dose Escalation phase.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:12 pm

SWTX

SpringWorks Therapeutics announced additional data from its Phase 3 DeFi trial of Nirogacestat in adults with desmoid tumors at the 2023 ASCO Meeting. The treatment demonstrated rapid, sustained, and consistent reductions in pain compared to placebo, as well as substantial reductions in MRI-assessed tumor volume and T2 hyperintensity.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:11 pm

IMAB

I-Mab reports positive Phase 1b/2 study results for uliledlimab and toripalimab combination therapy in advanced NSCLC patients at ASCO 2023. A biomarker-guided pivotal trial is being planned.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:11 pm

TCRT

Alaunos Therapeutics will present early data from its Phase 1/2 trial of TCR-T cell therapy at the 2023 ASCO Meeting. The therapy targets TP53 and KRAS driver mutations in solid tumors and has shown a manageable safety profile. The non-viral Sleeping Beauty cell engineering platform has demonstrated proof-of-concept in manufacturing TCR-T cell therapies.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:10 pm

XLO

Xilio Therapeutics announced preliminary clinical data from its Phase 1 trial of XTX101, a potential cancer treatment. The results showed promising safety and tolerability profiles.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:09 pm

THRX

Theseus Pharmaceuticals reports initial dose escalation data from its ongoing Phase 1/2 trial of THE-630 in patients with advanced GIST, showing an encouraging safety profile and evidence of clinical activity in heavily pre-treated patients.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:09 pm

INCY

Incyte announced that multiple abstracts featuring data from its oncology portfolio will be presented at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:08 pm